Validation of galectin-1 as potential diagnostic biomarker of early rheumatoid arthritis

Ana Triguero-Martínez,Santos Castañeda,Emilia Roy-Vallejo,Ana María Ortiz,Amalia Lamana,Isidoro González-Alvaro,Hortensia De La Fuente,Nuria Montes

doi:10.1038/s41598-020-74185-8

Ana Triguero-Martínez, Santos Castañeda + Show 6 more

Open Access

https://doi.org/10.1038/s41598-020-74185-8

Copy DOI

Abstract

Galectin 1 (Gal1) is a lectin with a wide cellular expression that functions as a negative regulator of the immune system in several animal models of autoimmune diseases. Identification of patients with rheumatoid arthritis (RA) has improved during the last decade, although there is still a need for biomarkers allowing an early diagnosis. In this regard, it has been recently proposed that Gal1 serum levels are increased in patients with RA compared to the general population. However, this topic is controversial in the literature. In this work, we provide additional information about the potential usefulness of Gal1 serum levels as a biomarker for RA diagnosis. We studied Gal1 serum and synovial fluid levels and clinical parameters in samples from 62 patients with early arthritis belonging to the PEARL study. In addition, 24 healthy donors were studied. We found that both patients fulfilling RA criteria and patients with undifferentiated arthritis showed higher Gal1 levels than healthy donors. Similar findings were observed in synovial fluid, which showed even higher levels than serum. However, we did not find correlation between Gal1 levels and disease activity or disability. Therefore, our results suggest that Gal1 could be a diagnostic but not a severity biomarker.

Highlights

Galectin 1 (Gal1) is a lectin with a wide cellular expression that functions as a negative regulator of the immune system in several animal models of autoimmune diseases
The landscape can be even more complex, since we have recently described that genetic variants in the region encoding for vasoactive intestinal peptide (VIP), which have not been associated with the risk of developing rheumatoid arthritis (RA), contribute to the heterogeneity of disease severity[8]
Patients were clustered in two different populations (Pop[1] and Population 2 (Pop2)) and 24 healthy donors (HD) were studied

Summary

Introduction

Galectin 1 (Gal1) is a lectin with a wide cellular expression that functions as a negative regulator of the immune system in several animal models of autoimmune diseases. Identification of patients with rheumatoid arthritis (RA) has improved during the last decade, there is still a need for biomarkers allowing an early diagnosis In this regard, it has been recently proposed that Gal[1] serum levels are increased in patients with RA compared to the general population. Some experts have suggested to treat intensively arthritis to abrogate inflammation[6], it seems wise to avoid over-treating patients less likely to develop a severe d isease[7] In this regard, the landscape can be even more complex, since we have recently described that genetic variants in the region encoding for vasoactive intestinal peptide (VIP), which have not been associated with the risk of developing RA, contribute to the heterogeneity of disease severity[8]. At least 15 mammalian galectins have been described, all containing 1 or 2 CRDs of approximately 130 amino

Objectives

Methods

Results

Conclusion